BPG is committed to discovery and dissemination of knowledge
Articles in Press
12/11/2025 7:14:53 AM | Browse: 24 | Download: 0
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Retrospective Study |
| Article Title |
Renal and metabolic effects of semaglutide plus canagliflozin vs canagliflozin alone in type 2 diabetic nephropathy
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yan Miao, Pan He, Dan-Yu Wang, Lei Yan, Hui-Xia Cao and Feng-Min Shao |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Major Public Welfare Projects in Henan Province |
201300310700 |
| Health Commission Project of Henan Province |
SBGJ202301001 |
|
| Corresponding Author |
Feng-Min Shao, Department of Nephrology, People's Hospital of Zhengzhou University and Henan Provincial People's Hospital, Henan Provincial Key Laboratory of Kidney Disease and Immunology, Henan Provincial Clinical Research Center for Kidney Disease, No. 7 Weiwu Road, Jinshui District, Zhengzhou 450003, Henan Province, China. shaofengmin123@163.com |
| Key Words |
Diabetic nephropathy; Semaglutide; Canagliflozin; Combination therapy; Glucose-lipid metabolism; Renoprotection |
| Core Tip |
This retrospective study demonstrates that, in individuals with type 2 diabetes and nephropathy, the addition of semaglutide to canagliflozin monotherapy provides better renal protection and metabolic improvements compared to canagliflozin alone. The combination significantly reduced proteinuria, improved glycemic and lipid control, enhanced β-cell function, alleviated systemic inflammation and oxidative stress, without increasing adverse events. It offers an effective and safe intensification therapy option, particularly for those who have not achieved optimal levels of proteinuria or metabolic parameters under sodium-glucose cotransporter-2 inhibitor monotherapy. |
| Citation |
Miao Y, He P, Wang DY, Yan L, Cao HX, Shao FM. Renal and metabolic effects of semaglutide plus canagliflozin vs canagliflozin alone in type 2 diabetic nephropathy. World J Diabetes 2025; In press |
 |
Received |
|
2025-08-26 09:23 |
 |
Peer-Review Started |
|
2025-08-27 00:45 |
 |
First Decision by Editorial Office Director |
|
2025-10-13 07:23 |
 |
Return for Revision |
|
2025-10-13 07:23 |
 |
Revised |
|
2025-10-28 08:42 |
 |
Publication Fee Transferred |
|
2025-11-03 07:58 |
 |
Second Decision by Editor |
|
2025-12-01 11:23 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2025-12-11 07:14 |
 |
Articles in Press |
|
2025-12-11 07:14 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345